MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Vaxart Inc

Fechado

0.32 -23.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.32

Máximo

0.32

Indicadores-chave

By Trading Economics

Rendimento

-3.6M

-16M

Vendas

5.7M

21M

Margem de lucro

-74.684

Funcionários

105

EBITDA

-3.6M

-12M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1521.62% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.4M

100M

Abertura anterior

24.13

Fecho anterior

0.32

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Vaxart Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de jul. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 de jul. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 de jul. de 2025, 23:05 UTC

Conversa de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 de jul. de 2025, 21:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de jul. de 2025, 21:36 UTC

Conversa de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

15 de jul. de 2025, 20:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 de jul. de 2025, 20:07 UTC

Ganhos

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 de jul. de 2025, 20:06 UTC

Conversa de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 de jul. de 2025, 19:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

15 de jul. de 2025, 19:54 UTC

Conversa de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 de jul. de 2025, 19:38 UTC

Conversa de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 de jul. de 2025, 19:09 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 de jul. de 2025, 19:07 UTC

Conversa de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 de jul. de 2025, 19:03 UTC

Conversa de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 de jul. de 2025, 18:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 de jul. de 2025, 18:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 de jul. de 2025, 18:13 UTC

Conversa de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 de jul. de 2025, 17:40 UTC

Conversa de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 de jul. de 2025, 17:40 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de jul. de 2025, 17:25 UTC

Aquisições, Fusões, Aquisições de Empresas

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 de jul. de 2025, 17:24 UTC

Conversa de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 de jul. de 2025, 16:49 UTC

Conversa de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

15 de jul. de 2025, 15:42 UTC

Conversa de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparação entre Pares

Variação de preço

Vaxart Inc Previsão

Preço-alvo

By TipRanks

1521.62% parte superior

Previsão para 12 meses

Média 6 USD  1521.62%

Máximo 8 USD

Mínimo 4 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Vaxart Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.4007 / 0.4252Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.